$350m collaboration deal for BMS and Five Prime Therapeutics

pharmafile | October 15, 2015 | News story | Research and Development BMS, Bristol-Myers Squibb, R&D, five prime, immuno-oncology, tumours 

Bristol-Myers Squibb has signed a collaboration agreement with the US biotech firm Five Prime Therapeutics, for a Colony Stimulating Factor 1 Receptor (CSF1R) antibody program.

The collaboration will aid the development and commercialisation of Five Prime’s colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008 which is in Phase I development for immunology and oncology indications.  It’s thought that CSF1R inhibition could block a key mediator, which suppresses the immune system in the tumour microenvironment.

Under the terms of the license and collaboration agreement, Bristol-Myers Squibb will make an upfront payment of $350 million to Five Prime, and will be responsible for development and manufacturing of FPA008 for all indications.

This agreement replaces the companies’ existing clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s programmed-death 1 (PD-1) immune checkpoint inhibitor, with FPA008 in six tumour types, announaced in November 2014. The the current Phase Ia/Ib trial trial will continue through to completion.

Francis Cuss, executive vice president and chief scientific officer of Bristol-Myers Squibb says: “This agreement, which builds upon our existing relationship with Five Prime in immuno-oncology, is another important example of our commitment to expanding our presence in this space and to researching novel combination regimens.”

Lewis Williams, president and chief executive of Five Prime Therapeutics says: “We believe this transformational collaboration with Bristol-Myers Squibb for our CSF1R antibody program represents the best of both worlds in terms of maximizing the potential of FPA008.”

“Bristol-Myers Squibb has undisputed leadership in the immuno-oncology landscape, deep clinical development and regulatory expertise, and an established commercial infrastructure to deliver important new therapies to patients. Bristol-Myers Squibb also has a rich pipeline of clinical candidates and approved products, a number of which may have therapeutic synergy when coupled with FPA008, given the potential of CSF1R inhibition to suppress the activity and survival of tumour associated macrophages.”

Yasmita Kumar

Related Content

BMS shares new research and development  plans at the company’s R&D day

Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …

NICE approves first treatment for obstructive HCM for NHS use

The National Institute for Health and Care Excellence (NICE) has announced that it has approved …


BioInvent and Transgene announce positive phase 1a solid tumour trial data

Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from …

Latest content